Literature DB >> 11738122

The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): clinical center recruitment experience.

J T Wright1, W C Cushman, B R Davis, J Barzilay, P Colon, D Egan, T Lucente, C Nwachuku, S Pressel, F H Leenen, J Frolkis, R Letterer, S Walsh, J N Tobin, G E Deger.   

Abstract

The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) is a randomized clinical outcome trial of antihypertensive and lipid-lowering therapy in a diverse population (including substantial numbers of women and minorities) of 42,419 high-risk hypertensives aged > or = 55 years with a planned mean follow-up of 6 years. In this paper, we describe our experience in the identification, recruitment, and selection of clinical centers for this large simple trial capable of meeting the recruitment goals outlined for ALLHAT, and we highlight factors associated with clinical center performance. Over 135,000 recruitment brochures were mailed to physicians. Requests for information and application packets were received from 9351 (6.8%) interested investigators. A total of 1053 completed applications were received and 909 sites (86%) were eventually approved to join the trial. Of the approved sites, 278 either later declined participation or were never activated, and 8 were closed within a year for lack of enrollment. The final 623 randomizing centers exceeded the trial's recruitment goal to enroll at least 40,000 participants into the trial, although the recruitment period was extended 1.5 years longer than planned. Fewer than a quarter of the sites (22.6%) were recruited from academic medical centers or Department of Veterans Affairs Medical Centers. More than half of the sites (54.7%) were private solo or group practices, which contributed 53% of randomized participants. Community health centers comprised about 8% of the ALLHAT sites and 2.9% were part of health maintenance organizations. More than 22% of the principal investigators reported that they had no previous clinical research experience. In summary, ALLHAT was successful in recruiting a diverse group of clinical centers to achieve its patient recruitment goals.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11738122     DOI: 10.1016/s0197-2456(01)00176-3

Source DB:  PubMed          Journal:  Control Clin Trials        ISSN: 0197-2456


  19 in total

1.  Clinical trial performance of community- vs university-based practices in the submacular surgery trials (SST): SST report no. 2.

Authors:  Neil M Bressler; Barbara S Hawkins; Susan B Bressler; Päivi H Miskala; Marta J Marsh
Journal:  Arch Ophthalmol       Date:  2004-06

2.  Recruitment and Screening for the Testosterone Trials.

Authors:  Jane A Cauley; Laura Fluharty; Susan S Ellenberg; Thomas M Gill; Kristine E Ensrud; Elizabeth Barrett-Connor; Denise Cifelli; Glenn R Cunningham; Alvin M Matsumoto; Shalender Bhasin; Marco Pahor; John T Farrar; David Cella; Raymond C Rosen; Susan M Resnick; Ronald S Swerdloff; Cora E Lewis; Mark E Molitch; Jill P Crandall; Alisa J Stephens-Shields; Thomas W Strorer; Christina Wang; Stephen Anton; Shehzad Basaria; Susan Diem; Vafa Tabatabaie; Darlene Dougar; Xiaoling Hou; Peter J Snyder
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2015-04-15       Impact factor: 6.053

3.  Participation in research studies: factors associated with failing to meet minority recruitment goals.

Authors:  Raegan W Durant; Roger B Davis; Diane Marie M St George; Ishan Canty Williams; Connie Blumenthal; Giselle M Corbie-Smith
Journal:  Ann Epidemiol       Date:  2007-05-25       Impact factor: 3.797

Review 4.  Evidence from clinical trials: can we do better?

Authors:  Andrew D Siderowf
Journal:  NeuroRx       Date:  2004-07

5.  Recruitment strategies and challenges in a large intervention trial: Systolic Blood Pressure Intervention Trial.

Authors:  Thomas M Ramsey; Joni K Snyder; Laura C Lovato; Christianne L Roumie; Steven P Glasser; Nora M Cosgrove; Christine M Olney; Rocky H Tang; Karen C Johnson; Carolyn H Still; Lisa H Gren; Jeffery C Childs; Osa L Crago; John H Summerson; Sandy M Walsh; Letitia H Perdue; Denise M Bankowski; David C Goff
Journal:  Clin Trials       Date:  2016-02-24       Impact factor: 2.486

6.  Absence of an interaction between the angiotensin-converting enzyme insertion-deletion polymorphism and pravastatin on cardiovascular disease in high-risk hypertensive patients: the Genetics of Hypertension-Associated Treatment (GenHAT) study.

Authors:  Anke-Hilse Maitland-van der Zee; Eric Boerwinkle; Donna K Arnett; Barry R Davis; Catherine Leiendecker-Foster; Michael B Miller; Olaf H Klungel; Charles E Ford; John H Eckfeldt
Journal:  Am Heart J       Date:  2007-01       Impact factor: 4.749

7.  Effect of Statin Treatment vs Usual Care on Primary Cardiovascular Prevention Among Older Adults: The ALLHAT-LLT Randomized Clinical Trial.

Authors:  Benjamin H Han; David Sutin; Jeff D Williamson; Barry R Davis; Linda B Piller; Hannah Pervin; Sara L Pressel; Caroline S Blaum
Journal:  JAMA Intern Med       Date:  2017-07-01       Impact factor: 21.873

8.  Site selection in community-based clinical trials for substance use disorders: strategies for effective site selection.

Authors:  Jennifer Sharpe Potter; Dennis M Donovan; Roger D Weiss; John Gardin; Robert Lindblad; Paul Wakim; Dorian Dodd
Journal:  Am J Drug Alcohol Abuse       Date:  2011-09       Impact factor: 3.829

9.  Improving Hawaiian and Filipino involvement in clinical research opportunities: qualitative findings from Hawai'i.

Authors:  Lisa X Gollin; Rosanne C Harrigan; José L Calderón; John Perez; David Easa
Journal:  Ethn Dis       Date:  2005       Impact factor: 1.847

10.  Interactions between the single nucleotide polymorphisms in the homocysteine pathway (MTHFR 677C>T, MTHFR 1298 A>C, and CBSins) and the efficacy of HMG-CoA reductase inhibitors in preventing cardiovascular disease in high-risk patients of hypertension: the GenHAT study.

Authors:  Anke-Hilse Maitland-van der Zee; Amy Lynch; Eric Boerwinkle; Donna K Arnett; Barry R Davis; Catherine Leiendecker-Foster; Charles E Ford; John H Eckfeldt
Journal:  Pharmacogenet Genomics       Date:  2008-08       Impact factor: 2.089

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.